MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15166161

Медицинская библиотека · Journal of clinical medicine · 2026

Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series.

Marasca Claudio, D'Amico Domenico, Giofrè Claudia, Lora Viviana

Клинический случайСтатьяПеревод в очереди

Аннотация

Background/

Objectives

Patients with a clinical diagnosis of severe psoriasis complicated by comorbidities such as cardiovascular disease, obesity, metabolic syndrome and/or with the involvement of high-impact areas constitute a clinical challenge. Tildrakizumab is a monoclonal antibody targeting the IL-23/Th17 axis with a proven record of efficacy and safety in these patients.

Methods

Here we present four cases of patients with severe psoriasis and comorbidities including cardiovascular disease (Case 1), obesity (Cases 2 and 3), metabolic syndrome (Case 3), and/or high-impact areas (Cases 2-4). Three patients (Cases 1-3) had previously received biologics but developed secondary failure or loss of efficacy; one patient was bio-naïve (Case 4).

Results

The treatment with tildrakizumab in all four patients led to a quick onset (by Week 4 in all cases) of complete and lasting (1 year in Case 1, 4 years in Case 2 and 2 years in Cases 3 and 4) remission with no adverse events reported.

Conclusions

Tildrakizumab is a valuable therapeutic option for patients with psoriasis and complex clinical situations, and in particular, in cases with obesity and difficult-to-treat lesion locations such as hands, scalp and genitals. Therapeutic success is often linked to an improvement in patients' quality of life.

Для цитирования: Marasca Claudio, D'Amico Domenico, Giofrè Claudia, Lora Viviana. Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15166161.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.